Ozempic European Public Assessment Report (EPAR)
Participants were eligible if we had the following data available at the start of treatment (day 0) and at the follow-up after one year (365 14 days): Before treatment initiation: sex, age (years), body weight (kg), waist circumference (cm), height (cm), body mass index (BMI), systolic and diastolic blood pressure, heart rate, and Edmonton Obesity Staging System (EOSS) score
Alternative pain management approaches should be considered: Topical NSAIDs gels or creams applied directly to painful areas (e.g., ibuprofen gel for muscle strains) provide localised relief with minimal systemic absorption Physical therapies heat or cold application, gentle exercise, physiotherapy Prescription alternatives your GP may recommend other analgesics depending on pain type and severity For specific pain types , tailored approaches work best
Clinical Trial Status: Where Each Compound Stands in 2026 Tirzepatide (Fully Approved) Tirzepatide completed its regulatory journey and received: FDA approval as Mounjaro (2022) for type 2 diabetes management FDA approval as Zepbound (2023) for chronic weight management in adults with obesity or overweight with weight-related comorbidities It is available via prescription from licensed healthcare providers in the United States and many other countries